November 20, 2024
The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the treatment of adults with moderate to severe hidradenitis […]
November 20, 2024
A population-based study has shown a slightly elevated risk for patients’ developing skin disorders, including alopecia areata (AA), alopecia totalis (AT), vitiligo, and bullous pemphigoid (BP), […]
November 20, 2024
TOPLINE: MEK inhibitors are frequently associated with cutaneous adverse events in pediatric patients, and binimetinib was associated with more severe reactions than selumetinib in a retrospective […]
November 19, 2024
The addition of dupilumab significantly reduced itching and hives compared with placebo in patients with chronic spontaneous urticaria (CSU) that was uncontrolled with H1-antihistamines, based on […]
November 19, 2024
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for dupilumab for the treatment of chronic spontaneous urticaria […]
November 18, 2024
LAS VEGAS — In the clinical experience of Julie C. Harper, MD, patients with ocular rosacea don’t always present with telltale signs like red or bloodshot […]
November 18, 2024
Sarah Cigna, MD, sees patients every week with vulvovaginal pain and vulvar dermatoses. She’s an ob.gyn. with a focus on sexual health — often the first […]
November 17, 2024
LAS VEGAS — After antifungal therapy for fungal nail disease, some dystrophy may persist, which can be addressed by several available treatments. Tracey C. Vlahovic, DPM […]
November 16, 2024
LAS VEGAS — Early in his career as a physician associate in dermatology, Joe Cari, MPAS, PA-C, received a negative online review from a patient that […]